Akero skyrockets after HARMONY study meets primary endpoints Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Akero Therapeutics (AKRO) up 114% after announcing its HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups, with 41% and 39% of EFX-treated patients, respectively, experiencing at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 24, compared with 20% for the placebo arm
- Akanda (AKAN) up 4% after entering an exclusive European license agreement with "iconic international cannabis lifestyle brand" Cookies
UP AFTER EARNINGS -
- Core & Main (CNM) up 9%
- Planet Labs (PL) up 8%
DOWN AFTER EARNINGS -
- Oracle (ORCL) down 1%
- Eastman Chemical (EMN) down 5%
- Rent The Runway (RENT) down 29%
- Braze (BRZE) down 8%
LOWER -
- Dow Inc. (DOW) down 2% after Jefferies analyst Laurence Alexander downgraded the stock to Hold from Buy with a price target of $45, down from $71
- Driven Brands (DRVN) down 7% after a 7M share secondary offering priced at $32.45
- Wolfspeed (WOLF) down 3% after Evercore ISI analyst Matthew Prisco initiated coverage of shares with an Outperform rating and $155 price target
Symbols:
AKAN WOLF AKRO CNM ORCL PL EMN RENT BRZE DOW DRVN Keywords: Fly Intel, Wall Street, Top Stories, Stocks